CIK 0001658551
- Non-accelerated filer
- Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464600503
- Phone
- +1 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,951,125
- in 9 filings, $8.0M under 10b5-1 plans
Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
- Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
- FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-04 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +24,372 | 24,372 | ||
| 2025-06-05 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-06 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-15 | Quimi Daphne Director | Purchase | +2,250 | $1.89 | $4K | 5,000 |
| 2024-05-14 | Quimi Daphne Director | Purchase | +2,750 | $1.89 | $5K | 2,750 |
| 2023-06-08 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +16,985 | 16,985 | ||
| 2022-06-09 | Quimi Daphne Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2022-01-06 | Quimi Daphne Director | Grant or award · Stock Option (Right to Buy) | +8,400 | 8,400 |
Page 1 of 1 · 8 trades